Literature DB >> 24506095

Burden of itch in epidermolysis bullosa.

J J L Snauwaert1, W Y Yuen, M F Jonkman, P Moons, G Naulaers, M A Morren.   

Abstract

BACKGROUND: Itch is an unpleasant feeling that leads to scratching. It is a common, but understudied, problem in patients with epidermolysis bullosa (EB).
OBJECTIVES: We measured the prevalence and characteristics of itch in the three major forms of EB: generalized EB simplex (EBS), junctional EB (JEB) and dystrophic EB (DEB).
METHODS: Forty patients with EB were recruited from two tertiary care centres and one patient organization. The sample included 19 patients with EBS, seven with JEB and 14 with DEB. Patients completed the Leuven Itch Scale (LIS), a multidimensional self-report instrument that quantifies the frequency, duration, severity, distress, consequences and surface area of itch. This instrument has good clinimetric properties.
RESULTS: Itch occurred in 85% of the patients, with substantial differences across the subtypes (EBS 74%, JEB 100%, DEB 93%). Itch, in all its dimensions, was most pronounced in patients with JEB and DEB, and less prominent in patients with EBS. The scores were significantly different for itch frequency, severity, distress and surface area, and the overall itch scores were comparable with those of atopic dermatitis. Itch mainly occurred in a hot environment (65%) and when sweating (62%). The most prevalent consequences were difficulty in falling asleep (88%) and lesions from scratching (85%). Differences between the three major subtypes were also observed in terms of circumstances, consequences and sensory characteristics.
CONCLUSIONS: As expected, itch is common among patients with EB. All aspects of itch measured by the LIS were more severe in JEB and DEB than in EBS.
© 2014 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2014        PMID: 24506095     DOI: 10.1111/bjd.12885

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  11 in total

1.  Prevalence and characterization of pruritus in epidermolysis bullosa.

Authors:  Christina Danial; Rasidat Adeduntan; Emily S Gorell; Anne W Lucky; Amy S Paller; Anna Bruckner; Elena Pope; Kimberly D Morel; Moise L Levy; Shufeng Li; Elaine S Gilmore; Alfred T Lane
Journal:  Pediatr Dermatol       Date:  2014-09-18       Impact factor: 1.588

2.  BP180 dysfunction triggers spontaneous skin inflammation in mice.

Authors:  Yang Zhang; Bin-Jin Hwang; Zhen Liu; Ning Li; Kendall Lough; Scott E Williams; Jinbo Chen; Susan W Burette; Luis A Diaz; Maureen A Su; Shengxiang Xiao; Zhi Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-04       Impact factor: 11.205

3.  Peripheral neuro-immune pathology in recessive dystrophic epidermolysis bullosa.

Authors:  Madison R Mack; Gwen Wendelschafer-Crabb; Brian D McAdams; Maria K Hordinsky; William R Kennedy; Jakub Tolar
Journal:  J Invest Dermatol       Date:  2014-11-14       Impact factor: 8.551

4.  Recessive dystrophic epidermolysis bullosa results in painful small fibre neuropathy.

Authors:  Sofia von Bischhoffshausen; Dinka Ivulic; Paola Alvarez; Victor C Schuffeneger; Juan Idiaquez; Constanza Fuentes; Pilar Morande; Ignacia Fuentes; Francis Palisson; David L H Bennett; Margarita Calvo
Journal:  Brain       Date:  2017-05-01       Impact factor: 13.501

Review 5.  Psychosocial recommendations for the care of children and adults with epidermolysis bullosa and their family: evidence based guidelines.

Authors:  K Martin; S Geuens; J K Asche; R Bodan; F Browne; A Downe; N García García; G Jaega; B Kennedy; P J Mauritz; F Pérez; K Soon; V Zmazek; K M Mayre-Chilton
Journal:  Orphanet J Rare Dis       Date:  2019-06-11       Impact factor: 4.123

6.  Beneficial Effect of Systemic Allogeneic Adipose Derived Mesenchymal Cells on the Clinical, Inflammatory and Immunologic Status of a Patient With Recessive Dystrophic Epidermolysis Bullosa: A Case Report.

Authors:  Rocío Maseda; Lucía Martínez-Santamaría; Rosa Sacedón; Nora Butta; María Del Carmen de Arriba; Sara García-Barcenilla; Marta García; Nuria Illera; Isabel Pérez-Conde; Marta Carretero; Eva Jiménez; Gustavo Melen; Alberto M Borobia; Víctor Jiménez-Yuste; Ángeles Vicente; Marcela Del Río; Raúl de Lucas; María José Escámez
Journal:  Front Med (Lausanne)       Date:  2020-11-26

7.  Intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients.

Authors:  Sang Eun Lee; Seung-Ju Lee; Song-Ee Kim; Kinam Kim; Boyoung Cho; Kyounghwan Roh; Soo-Chan Kim
Journal:  JCI Insight       Date:  2021-01-25

8.  Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa.

Authors:  Dimitra Kiritsi; Kathrin Dieter; Elke Niebergall-Roth; Silvia Fluhr; Cristina Daniele; Jasmina Esterlechner; Samar Sadeghi; Seda Ballikaya; Leoni Erdinger; Franziska Schauer; Stella Gewert; Martin Laimer; Johann W Bauer; Alain Hovnanian; Giovanna Zambruno; May El Hachem; Emmanuelle Bourrat; Maria Papanikolaou; Gabriela Petrof; Sophie Kitzmüller; Christen L Ebens; Markus H Frank; Natasha Y Frank; Christoph Ganss; Anna E Martinez; John A McGrath; Jakub Tolar; Mark A Kluth
Journal:  JCI Insight       Date:  2021-11-22

9.  Identifying Epidermolysis Bullosa Patient Needs and Perceived Treatment Benefits: An Explorative Study Using the Patient Benefit Index.

Authors:  Nicholas H B Schräder; Eva W H Korte; José C Duipmans; Roy E Stewart; Maria C Bolling; André P Wolff
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241

10.  Translational perspectives to treat Epidermolysis bullosa-Where do we stand?

Authors:  Christine Prodinger; Johann W Bauer; Martin Laimer
Journal:  Exp Dermatol       Date:  2020-11       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.